search icon
valn-img

Valneva SE ADR, Common Stock

VALN

NSQ

$6.34

-$0.11

(-1.71%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$569.14M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
8.30K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.29
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.62 L
$9.5 H
$6.34

About Valneva SE ADR, Common Stock

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate which is in Phase III clinical trial against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a Phase I vaccine candidate targeting the Zika virus (ZIKV), a mosquito-borne viral disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVALNSectorS&P500
1-Week Return-5.29%3.12%5.2%
1-Month Return-3.87%-4.61%-0.86%
3-Month Return27.22%-4.38%-7.94%
6-Month Return7.68%-6.15%-4.73%
1-Year Return-16.12%-0.82%8.67%
3-Year Return-75.22%6.9%34.54%
5-Year Return-77.25%39.02%89.09%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue110.32M348.08M361.30M153.71M169.58M[{"date":"2020-12-31","value":30.53,"profit":true},{"date":"2021-12-31","value":96.34,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":42.54,"profit":true},{"date":"2024-12-31","value":46.94,"profit":true}]
Cost of Revenue54.30M187.92M324.44M100.88M98.54M[{"date":"2020-12-31","value":16.74,"profit":true},{"date":"2021-12-31","value":57.92,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":31.09,"profit":true},{"date":"2024-12-31","value":30.37,"profit":true}]
Gross Profit56.02M160.16M36.86M52.84M71.04M[{"date":"2020-12-31","value":34.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":23.02,"profit":true},{"date":"2023-12-31","value":32.99,"profit":true},{"date":"2024-12-31","value":44.35,"profit":true}]
Gross Margin50.78%46.01%10.20%34.37%41.89%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":90.62,"profit":true},{"date":"2022-12-31","value":20.09,"profit":true},{"date":"2023-12-31","value":67.69,"profit":true},{"date":"2024-12-31","value":82.5,"profit":true}]
Operating Expenses111.13M221.56M150.31M134.92M57.71M[{"date":"2020-12-31","value":50.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":67.84,"profit":true},{"date":"2023-12-31","value":60.9,"profit":true},{"date":"2024-12-31","value":26.05,"profit":true}]
Operating Income(55.11M)(61.39M)(113.44M)(82.09M)13.33M[{"date":"2020-12-31","value":-413.43,"profit":false},{"date":"2021-12-31","value":-460.55,"profit":false},{"date":"2022-12-31","value":-851.04,"profit":false},{"date":"2023-12-31","value":-615.81,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(20.80M)(25.30M)(50.17M)(33.75M)(46.44M)[{"date":"2020-12-31","value":-2080200000,"profit":false},{"date":"2021-12-31","value":-2530300000,"profit":false},{"date":"2022-12-31","value":-5016600000,"profit":false},{"date":"2023-12-31","value":-3375300000,"profit":false},{"date":"2024-12-31","value":-4643800000,"profit":false}]
Pre-Tax Income(65.30M)(69.98M)(144.81M)(98.63M)(11.49M)[{"date":"2020-12-31","value":-6530200000,"profit":false},{"date":"2021-12-31","value":-6997900000,"profit":false},{"date":"2022-12-31","value":-14481500000,"profit":false},{"date":"2023-12-31","value":-9862900000,"profit":false},{"date":"2024-12-31","value":-1148600000,"profit":false}]
Income Taxes(909.00K)3.45M(1.54M)2.80M761.00K[{"date":"2020-12-31","value":-26.38,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-44.57,"profit":false},{"date":"2023-12-31","value":81.25,"profit":true},{"date":"2024-12-31","value":22.08,"profit":true}]
Income After Taxes(64.39M)(73.42M)(143.28M)(101.43M)(12.25M)[{"date":"2020-12-31","value":-6439300000,"profit":false},{"date":"2021-12-31","value":-7342500000,"profit":false},{"date":"2022-12-31","value":-14327900000,"profit":false},{"date":"2023-12-31","value":-10142900000,"profit":false},{"date":"2024-12-31","value":-1224700000,"profit":false}]
Income From Continuous Operations(64.39M)(73.42M)(143.28M)(113.47M)(12.25M)[{"date":"2020-12-31","value":-6439300000,"profit":false},{"date":"2021-12-31","value":-7342500000,"profit":false},{"date":"2022-12-31","value":-14327900000,"profit":false},{"date":"2023-12-31","value":-11347500000,"profit":false},{"date":"2024-12-31","value":-1224700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(64.39M)(73.42M)(143.28M)(101.43M)(12.25M)[{"date":"2020-12-31","value":-6439300000,"profit":false},{"date":"2021-12-31","value":-7342500000,"profit":false},{"date":"2022-12-31","value":-14327900000,"profit":false},{"date":"2023-12-31","value":-10142900000,"profit":false},{"date":"2024-12-31","value":-1224700000,"profit":false}]
EPS (Diluted)(1.32)(1.69)(2.63)(1.33)(0.13)[{"date":"2020-12-31","value":-132.46,"profit":false},{"date":"2021-12-31","value":-168.67,"profit":false},{"date":"2022-12-31","value":-262.58,"profit":false},{"date":"2023-12-31","value":-133,"profit":false},{"date":"2024-12-31","value":-13.25,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VALN
Cash Ratio 1.47
Current Ratio 2.61
Quick Ratio 2.14

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VALN
ROA (LTM) -10.03%
ROE (LTM) -7.91%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VALN
Debt Ratio Lower is generally better. Negative is bad. 0.64
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.36

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VALN
Trailing PE NM
Forward PE 666.67
P/S (TTM) 3.29
P/B 2.62
Price/FCF 99
EV/R 3.19
EV/Ebitda 16.85

FAQs

What is Valneva SE ADR share price today?

Valneva SE ADR (VALN) share price today is $6.34

Can Indians buy Valneva SE ADR shares?

Yes, Indians can buy shares of Valneva SE ADR (VALN) on Vested. To buy Valneva SE ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VALN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Valneva SE ADR be purchased?

Yes, you can purchase fractional shares of Valneva SE ADR (VALN) via the Vested app. You can start investing in Valneva SE ADR (VALN) with a minimum investment of $1.

How to invest in Valneva SE ADR shares from India?

You can invest in shares of Valneva SE ADR (VALN) via Vested in three simple steps:

  • Click on Sign Up or Invest in VALN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Valneva SE ADR shares
What is Valneva SE ADR 52-week high and low stock price?

The 52-week high price of Valneva SE ADR (VALN) is $9.5. The 52-week low price of Valneva SE ADR (VALN) is $3.62.

What is Valneva SE ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Valneva SE ADR (VALN) is 2.62

What is the Market Cap of Valneva SE ADR?

The market capitalization of Valneva SE ADR (VALN) is $569.14M

What is Valneva SE ADR’s stock symbol?

The stock symbol (or ticker) of Valneva SE ADR is VALN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top